Ottawa, Ontario – (Marketwired – September 29, 2016) – Tetra Brio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP), through its wholly-owned subsidiary, PhytoPain Pharma Inc. (“PPP”), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions, has selected Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry.